Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 18;10(5):1240.
doi: 10.3390/cells10051240.

Targeting the VEGF Pathway in Osteosarcoma

Tarek Assi  1 , Sarah Watson  2 , Bachar Samra  3 , Elie Rassy  4 , Axel Le Cesne  5 , Antoine Italiano  5   6 , Olivier Mir  5
Affiliations
Review

Targeting the VEGF Pathway in Osteosarcoma

Tarek Assi et al. Cells. .

Abstract

Osteosarcoma is the most common primary tumor of the bones affecting mainly young adults. Despite the advances in the field of systemic anticancer therapy, the prognosis of relapsed of metastatic osteosarcoma patients remain dismal with very short survival. However, the better understanding of the pathophysiology of this subtype of sarcoma has led to the identification of new targeted agents with significant activity. In fact, increased angiogenesis plays a major role in the tumor growth and survival of osteosarcoma patients. Several targeted agents have demonstrated a significant anti-tumor activity including multi-kinase inhibitors. In this review, we will discuss the pathophysiology, rationale, and role of targeting angiogenesis via the VEGF pathway in patients with osteosarcoma with emphasis on the published clinical trials and future directions.

Keywords: angiogenesis; bone neoplasms; osteosarcoma; protein kinase inhibitors; sarcoma; vascular endothelial growth factor A.

PubMed Disclaimer

Conflict of interest statement

Assi has received honorarium from Amgen, MSD and Abbvie. Mir has acted as consultant for Amgen, Astra-Zeneca, Bayer, Bristol Myers-Squibb, Eli-Lilly, Ipsen, Lundbeck, MSD, Novartis, Pfizer, Roche, Servier, and Vifor Pharma.

Figures

Figure 1
Figure 1
VEGF pathway in osteosarcoma and potential therapeutic targets.
See this image and copyright information in PMC

References

    1. WHO Classification of Tumours of Soft Tissue and Bone. Fourth Edition—WHO—OMS—[Internet] [(accessed on 14 October 2018)]; Available online: http://apps.who.int/bookorders/WHP/detart1.jsp?sesslan=1&codlan=1&codcol....
    1. Raymond A.K., Jaffe N. Cancer Treatment and Research. Volume 152. Springer; Boston, MA, USA: 2009. Osteosarcoma Multidisciplinary Approach to the Management from the Pathologist’s Perspective; pp. 63–84. - PubMed
    1. Marko T.A., Diessner B.J., Spector L.G. Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison. Pediatr. Blood Cancer. 2016;63:1006–1011. doi: 10.1002/pbc.25963. - DOI - PMC - PubMed
    1. Ferrari S., Briccoli A., Mercuri M., Bertoni F., Picci P., Tienghi A., Del Prever A.B., Fagioli F., Comandone A., Bacci G. Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival. J. Clin. Oncol. 2003;21:710–715. doi: 10.1200/JCO.2003.03.141. - DOI - PubMed
    1. De Bree E., Drositis I., Michelakis D., Mavroudis D. Resection of Pulmonary Metastases in Osteosarcoma. Is it Justified? Hell J. Surg. 2018;90:293–298. doi: 10.1007/s13126-018-0493-8. - DOI

MeSH terms

Substances